Haemonetics Financial Statements From 2010 to 2025

HAE Stock  USD 64.80  0.72  1.10%   
Haemonetics financial statements provide useful quarterly and yearly information to potential Haemonetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Haemonetics financial statements helps investors assess Haemonetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Haemonetics' valuation are summarized below:
Gross Profit
768.3 M
Profit Margin
0.0947
Market Capitalization
3.3 B
Enterprise Value Revenue
3.0546
Revenue
1.4 B
There are over one hundred nineteen available fundamental trends for Haemonetics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Haemonetics' regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Haemonetics Total Revenue

1.58 Billion

Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.6 B or Gross Profit of 835 M, as well as many indicators such as Price To Sales Ratio of 2.15, Dividend Yield of 0.0098 or PTB Ratio of 2.79. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding42.5 M46.3 M51.2 M
Slightly volatile
Total Assets2.7 B2.5 B1.6 B
Slightly volatile
Short and Long Term Debt Total975.4 M929 M502.6 M
Slightly volatile
Other Current Liabilities224.1 M213.4 M121.7 M
Slightly volatile
Total Current Liabilities362.7 M345.4 M250.7 M
Slightly volatile
Total Stockholder Equity1.2 B1.1 B765.6 M
Slightly volatile
Property Plant And Equipment Net442.7 M421.6 M291.7 M
Slightly volatile
Retained Earnings281.9 M414.5 M280.8 M
Very volatile
Accounts Payable88.6 M84.4 M54.2 M
Slightly volatile
Cash138.4 M205.6 M172.8 M
Slightly volatile
Non Current Assets Total1.7 B1.6 B934 M
Slightly volatile
Non Currrent Assets Other99.2 M93.3 M169.5 M
Slightly volatile
Cash And Short Term Investments140.6 M205.6 M172.9 M
Slightly volatile
Net Receivables120.7 M237.5 M155.7 M
Slightly volatile
Liabilities And Stockholders Equity2.7 B2.5 B1.6 B
Slightly volatile
Non Current Liabilities Total1.1 B1.1 B536.3 M
Slightly volatile
Inventory383 M364.8 M229.3 M
Slightly volatile
Other Current Assets40.1 M76.3 M51.4 M
Slightly volatile
Other Stockholder Equity766.3 M729.8 M499.7 M
Slightly volatile
Total Liabilities1.5 B1.4 B787 M
Slightly volatile
Property Plant And Equipment Gross1.2 B1.1 B497.1 M
Slightly volatile
Total Current Assets928.5 M884.2 M618.7 M
Slightly volatile
Short Term Debt11.2 M11.8 M49.6 M
Very volatile
Intangible Assets490.4 M467 M249.9 M
Slightly volatile
Common Stock Total Equity421 K579.6 K479.2 K
Slightly volatile
Common Stock419.7 K584.2 K481.5 K
Slightly volatile
Other Liabilities131.1 M124.9 M61.7 M
Slightly volatile
Other Assets1.091.1519.4 M
Very volatile
Long Term Debt963.1 M917.2 M455.4 M
Slightly volatile
Good Will682.3 M649.8 M345.4 M
Slightly volatile
Property Plant Equipment213.6 M357.5 M275.8 M
Slightly volatile
Retained Earnings Total Equity230.9 M227.9 M279 M
Slightly volatile
Long Term Debt Total910.6 M867.2 M444 M
Slightly volatile
Capital Surpluse516.6 M683.9 M493.8 M
Slightly volatile
Deferred Long Term Liabilities26.4 M41.6 M26.1 M
Slightly volatile
Non Current Liabilities Other55.7 M86.3 M53.2 M
Slightly volatile
Deferred Long Term Asset Charges3.3 MM3.5 M
Slightly volatile
Short and Long Term Debt8.7 M9.2 M152.9 M
Slightly volatile
Cash And Equivalents214.1 M327.1 M189.1 M
Slightly volatile
Net Invested Capital1.1 BB1.1 B
Slightly volatile
Net Working Capital400.1 M538.8 M277.5 M
Slightly volatile
Capital Stock406 K457.2 K499.3 K
Slightly volatile
Capital Lease Obligations6.2 M6.5 M43.6 M
Slightly volatile

Haemonetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue1.6 B1.5 B981.8 M
Slightly volatile
Gross Profit835 M795.3 M487.3 M
Slightly volatile
EBITDA320.7 M305.4 M179.9 M
Slightly volatile
Depreciation And Amortization117.4 M111.8 M86.3 M
Slightly volatile
Other Operating Expenses1.4 B1.3 B856.3 M
Slightly volatile
Cost Of Revenue745.6 M710.1 M499.5 M
Slightly volatile
Total Operating Expenses635.9 M605.7 M391.4 M
Slightly volatile
Research Development33.3 M62.6 M42.4 M
Slightly volatile
Selling General Administrative512.8 M488.4 M325 M
Slightly volatile
Selling And Marketing Expenses4.8 M8.2 M4.7 M
Slightly volatile
Non Recurring630.4 K663.5 K20.4 M
Pretty Stable
Interest Income13.3 M16.8 M11.8 M
Slightly volatile
Reconciled Depreciation77.9 M87.5 M92 M
Very volatile

Haemonetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow139.4 M132.8 M78.7 M
Slightly volatile
Begin Period Cash Flow343.5 M327.1 M194.2 M
Slightly volatile
Depreciation117.4 M111.8 M86.3 M
Slightly volatile
Capital Expenditures54.3 M76.2 M74 M
Pretty Stable
Total Cash From Operating Activities107 M209 M147.3 M
Slightly volatile
End Period Cash Flow138.4 M205.6 M172.8 M
Slightly volatile
Change To Netincome40.4 M41.6 M38.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.154.26982.9726
Slightly volatile
Dividend Yield0.00980.0110.012
Slightly volatile
PTB Ratio2.795.12953.9404
Slightly volatile
Days Sales Outstanding77.5561.064461.6831
Pretty Stable
Book Value Per Share7.5714.262714.2204
Slightly volatile
Free Cash Flow Yield0.03250.03770.0388
Slightly volatile
Operating Cash Flow Per Share4.394.17694.0029
Slightly volatile
Stock Based Compensation To Revenue0.01380.01440.0158
Slightly volatile
Capex To Depreciation1.30.83810.9958
Slightly volatile
PB Ratio2.795.12953.9404
Slightly volatile
EV To Sales2.224.35113.2436
Slightly volatile
Free Cash Flow Per Share2.92.7592.3435
Slightly volatile
Inventory Turnover2.953.05982.5007
Pretty Stable
Days Of Inventory On Hand117119150
Pretty Stable
Payables Turnover8.078.90289.7054
Slightly volatile
Sales General And Administrative To Revenue0.370.34670.3314
Very volatile
Research And Ddevelopement To Revenue0.05670.04340.0442
Very volatile
Capex To Revenue0.06480.08270.0852
Slightly volatile
Cash Per Share2.023.41523.7685
Slightly volatile
POCF Ratio14.717.515614.8645
Slightly volatile
Payout Ratio0.190.220.2347
Slightly volatile
Capex To Operating Cash Flow0.630.33950.4407
Pretty Stable
PFCF Ratio40.0826.516926.7704
Slightly volatile
Days Payables Outstanding43.2640.998238.5992
Slightly volatile
EV To Operating Cash Flow15.217.849216.2201
Slightly volatile
EV To Free Cash Flow42.3327.021929.2036
Slightly volatile
Intangibles To Total Assets0.170.29740.3186
Slightly volatile
Net Debt To EBITDA0.480.48041.8763
Slightly volatile
Current Ratio1.291.35482.5255
Pretty Stable
Receivables Turnover4.225.97735.9499
Pretty Stable
Graham Number10.7816.649825.5579
Very volatile
Shareholders Equity Per Share7.5714.262714.2204
Slightly volatile
Debt To Equity0.270.33720.6236
Slightly volatile
Capex Per Share0.771.41791.6144
Pretty Stable
Revenue Per Share9.1117.134418.6681
Slightly volatile
Interest Debt Per Share3.44.89459.7481
Slightly volatile
Debt To Assets0.140.2050.3015
Pretty Stable
Enterprise Value Over EBITDA26.9925.700624.088
Pretty Stable
Short Term Coverage Ratios1.081.134311.0216
Slightly volatile
Operating Cycle239180214
Slightly volatile
Price Book Value Ratio2.795.12953.9404
Slightly volatile
Days Of Payables Outstanding43.2640.998238.5992
Slightly volatile
Dividend Payout Ratio0.190.220.2347
Slightly volatile
Price To Operating Cash Flows Ratio14.717.515614.8645
Slightly volatile
Price To Free Cash Flows Ratio40.0826.516926.7704
Slightly volatile
Ebt Per Ebit0.781.06191.0949
Slightly volatile
Effective Tax Rate0.320.23580.1537
Slightly volatile
Company Equity Multiplier1.311.64451.9483
Slightly volatile
Long Term Debt To Capitalization0.140.07320.3277
Pretty Stable
Total Debt To Capitalization0.180.25210.3653
Slightly volatile
Debt Equity Ratio0.270.33720.6236
Slightly volatile
Quick Ratio0.890.93681.6657
Pretty Stable
Dividend Paid And Capex Coverage Ratio1.712.94592.3217
Slightly volatile
Net Income Per E B T0.430.76420.831
Slightly volatile
Cash Ratio0.720.46830.8262
Pretty Stable
Cash Conversion Cycle142139172
Very volatile
Operating Cash Flow Sales Ratio0.130.24380.1993
Pretty Stable
Days Of Inventory Outstanding117119150
Pretty Stable
Days Of Sales Outstanding77.5561.064461.6831
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.340.66050.5574
Pretty Stable
Cash Flow Coverage Ratios0.830.86860.4893
Very volatile
Price To Book Ratio2.795.12953.9404
Slightly volatile
Fixed Asset Turnover4.152.72143.3012
Slightly volatile
Capital Expenditure Coverage Ratio1.732.94592.323
Slightly volatile
Price Cash Flow Ratio14.717.515614.8645
Slightly volatile
Enterprise Value Multiple26.9925.700624.088
Pretty Stable
Debt Ratio0.140.2050.3015
Pretty Stable
Cash Flow To Debt Ratio0.830.86860.4893
Very volatile
Price Sales Ratio2.154.26982.9726
Slightly volatile
Asset Turnover0.890.73050.6831
Pretty Stable
Gross Profit Margin0.570.45570.4898
Slightly volatile
Price Fair Value2.795.12953.9404
Slightly volatile

Haemonetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B1.9 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.8 B
Slightly volatile

Haemonetics Fundamental Market Drivers

Forward Price Earnings13.1062
Cash And Short Term Investments178.8 M

Haemonetics Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue35.9 M22.5 M
Total Revenue1.5 B1.6 B
Cost Of Revenue710.1 M745.6 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.35  0.37 
Research And Ddevelopement To Revenue 0.04  0.06 
Capex To Revenue 0.08  0.06 
Revenue Per Share 17.13  9.11 
Ebit Per Revenue 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.213
Earnings Share
2.54
Revenue Per Share
27.076
Quarterly Revenue Growth
0.037
Return On Assets
0.0633
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.